Literature DB >> 28806897

Evaluation of Intrathecal Routes of Administration for Adeno-Associated Viral Vectors in Large Animals.

Christian Hinderer1, Peter Bell1, Nathan Katz1, Charles H Vite2, Jean-Pierre Louboutin3, Erin Bote1, Hongwei Yu1, Yanqing Zhu1, Margret L Casal2, Jessica Bagel2, Patricia O'Donnell2, Ping Wang2, Mark E Haskins2, Tamara Goode1, James M Wilson1.   

Abstract

Delivery of adeno-associated viral (AAV) vectors into the cerebrospinal fluid (CSF) can achieve gene transfer to cells throughout the brain and spinal cord, potentially making many neurological diseases tractable gene therapy targets. Identifying the optimal route of CSF access for intrathecal AAV delivery will be a critical step in translating this approach to clinical practice. We previously demonstrated that vector injection into the cisterna magna is a safe and effective method for intrathecal AAV delivery in nonhuman primates; however, this procedure is not commonly used in clinical practice. More routine methods of administration into the CSF are now being explored, including intracerebroventricular (ICV) injection and injection through a lumbar puncture. In this study, we compared ICV and intracisternal (IC) AAV administration in dogs. We also evaluated vector administration via lumbar puncture in nonhuman primates, with some animals placed in the Trendelenburg position after injection, a maneuver that has been suggested to improve cranial distribution of vector. In the dog study, ICV and IC vector administration resulted in similarly efficient transduction throughout the brain and spinal cord. However, animals in the ICV cohort developed encephalitis associated with a T-cell response to the transgene product, a phenomenon that was not observed in the IC cohort. In the nonhuman primate study, transduction efficiency was not improved by placing animals in the Trendelenburg position after injection. These findings illustrate important limitations of commonly used methods for CSF access in the context of AAV delivery, and will be important for informing the selection of a route of administration for first-in-human studies.

Entities:  

Keywords:  AAV; GUSB; central nervous system; gene therapy; intrathecal; mucopolysaccharidosis

Mesh:

Year:  2017        PMID: 28806897      PMCID: PMC5770082          DOI: 10.1089/hum.2017.026

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  18 in total

1.  Intrathecal gene therapy corrects CNS pathology in a feline model of mucopolysaccharidosis I.

Authors:  Christian Hinderer; Peter Bell; Brittney L Gurda; Qiang Wang; Jean-Pierre Louboutin; Yanqing Zhu; Jessica Bagel; Patricia O'Donnell; Tracey Sikora; Therese Ruane; Ping Wang; Mark E Haskins; James M Wilson
Journal:  Mol Ther       Date:  2014-07-16       Impact factor: 11.454

2.  Impact of pre-existing immunity on gene transfer to nonhuman primate liver with adeno-associated virus 8 vectors.

Authors:  Lili Wang; Roberto Calcedo; Peter Bell; Jianping Lin; Rebecca L Grant; Don L Siegel; James M Wilson
Journal:  Hum Gene Ther       Date:  2011-06-08       Impact factor: 5.695

3.  Long-term evaluation of a phase 1 study of AADC gene therapy for Parkinson's disease.

Authors:  Gabriele Mittermeyer; Chadwick W Christine; Kathryn H Rosenbluth; Suzanne L Baker; Philip Starr; Paul Larson; Paul L Kaplan; John Forsayeth; Michael J Aminoff; Krystof S Bankiewicz
Journal:  Hum Gene Ther       Date:  2012-04-10       Impact factor: 5.695

4.  Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.

Authors:  Christian Hinderer; Peter Bell; Jean-Pierre Louboutin; Yanqing Zhu; Hongwei Yu; Gloria Lin; Ruth Choa; Brittney L Gurda; Jessica Bagel; Patricia O'Donnell; Tracey Sikora; Therese Ruane; Ping Wang; Alice F Tarantal; Margret L Casal; Mark E Haskins; James M Wilson
Journal:  Mol Ther       Date:  2015-05-29       Impact factor: 11.454

5.  Improving single injection CSF delivery of AAV9-mediated gene therapy for SMA: a dose-response study in mice and nonhuman primates.

Authors:  Kathrin Meyer; Laura Ferraiuolo; Leah Schmelzer; Lyndsey Braun; Vicki McGovern; Shibi Likhite; Olivia Michels; Alessandra Govoni; Julie Fitzgerald; Pablo Morales; Kevin D Foust; Jerry R Mendell; Arthur H M Burghes; Brian K Kaspar
Journal:  Mol Ther       Date:  2014-10-31       Impact factor: 11.454

6.  Gene therapy of the brain in the dog model of Hurler's syndrome.

Authors:  Carine Ciron; Nathalie Desmaris; Marie-Anne Colle; Sylvie Raoul; Béatrice Joussemet; Lucie Vérot; Jérôme Ausseil; Roseline Froissart; Françoise Roux; Yan Chérel; Nicolas Ferry; Yaouen Lajat; Bertrand Schwartz; Marie-Thérèse Vanier; Irène Maire; Marc Tardieu; Philippe Moullier; Jean-Michel Heard
Journal:  Ann Neurol       Date:  2006-08       Impact factor: 10.422

7.  Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral vectors at scale.

Authors:  Martin Lock; Mauricio Alvira; Luk H Vandenberghe; Arabinda Samanta; Jaan Toelen; Zeger Debyser; James M Wilson
Journal:  Hum Gene Ther       Date:  2010-10       Impact factor: 5.695

8.  Whole body correction of mucopolysaccharidosis IIIA by intracerebrospinal fluid gene therapy.

Authors:  Virginia Haurigot; Sara Marcó; Albert Ribera; Miguel Garcia; Albert Ruzo; Pilar Villacampa; Eduard Ayuso; Sònia Añor; Anna Andaluz; Mercedes Pineda; Gemma García-Fructuoso; Maria Molas; Luca Maggioni; Sergio Muñoz; Sandra Motas; Jesús Ruberte; Federico Mingozzi; Martí Pumarola; Fatima Bosch
Journal:  J Clin Invest       Date:  2013-07-01       Impact factor: 14.808

9.  Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates.

Authors:  S J Gray; S Nagabhushan Kalburgi; T J McCown; R Jude Samulski
Journal:  Gene Ther       Date:  2013-01-10       Impact factor: 5.250

10.  Evaluation of AAV-mediated Gene Therapy for Central Nervous System Disease in Canine Mucopolysaccharidosis VII.

Authors:  Brittney L Gurda; Adrien De Guilhem De Lataillade; Peter Bell; Yanqing Zhu; Hongwei Yu; Ping Wang; Jessica Bagel; Charles H Vite; Tracey Sikora; Christian Hinderer; Roberto Calcedo; Alexander D Yox; Richard A Steet; Therese Ruane; Patricia O'Donnell; Guangping Gao; James M Wilson; Margret Casal; Katherine P Ponder; Mark E Haskins
Journal:  Mol Ther       Date:  2015-10-08       Impact factor: 11.454

View more
  36 in total

1.  AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease.

Authors:  Jonathan B Rosenberg; Michael G Kaplitt; Bishnu P De; Alvin Chen; Thomas Flagiello; Christiana Salami; Eduard Pey; Lingzhi Zhao; Rodolfo J Ricart Arbona; Sebastien Monette; Jonathan P Dyke; Douglas J Ballon; Stephen M Kaminsky; Dolan Sondhi; Gregory A Petsko; Steven M Paul; Ronald G Crystal
Journal:  Hum Gene Ther Clin Dev       Date:  2018-03-13       Impact factor: 5.032

Review 2.  Challenges of gene delivery to the central nervous system and the growing use of biomaterial vectors.

Authors:  Devan L Puhl; Anthony R D'Amato; Ryan J Gilbert
Journal:  Brain Res Bull       Date:  2019-06-05       Impact factor: 4.077

Review 3.  Adeno-associated virus-based Alzheimer's disease mouse models and potential new therapeutic avenues.

Authors:  Lars M Ittner; Matthias Klugmann; Yazi D Ke
Journal:  Br J Pharmacol       Date:  2019-04-23       Impact factor: 8.739

Review 4.  Gene therapy for neurological disorders: progress and prospects.

Authors:  Benjamin E Deverman; Bernard M Ravina; Krystof S Bankiewicz; Steven M Paul; Dinah W Y Sah
Journal:  Nat Rev Drug Discov       Date:  2018-08-10       Impact factor: 84.694

5.  Slow Infusion of Recombinant Adeno-Associated Viruses into the Mouse Cerebrospinal Fluid Space.

Authors:  Dan Wang; Jia Li; Karen Tran; Daniel R Burt; Li Zhong; Guangping Gao
Journal:  Hum Gene Ther Methods       Date:  2018-03-29       Impact factor: 2.396

6.  A Safe and Reliable Technique for CNS Delivery of AAV Vectors in the Cisterna Magna.

Authors:  Toloo Taghian; Miklos G Marosfoi; Ajit S Puri; Oguz I Cataltepe; Robert M King; Elise B Diffie; Anne S Maguire; Douglas R Martin; Deborah Fernau; Ana Rita Batista; Tim Kuchel; Chris Christou; Raj Perumal; Sundeep Chandra; Paul D Gamlin; Stephanie G Bertrand; Terence R Flotte; Diane McKenna-Yasek; Phillip W L Tai; Neil Aronin; Matthew J Gounis; Miguel Sena-Esteves; Heather L Gray-Edwards
Journal:  Mol Ther       Date:  2019-11-16       Impact factor: 11.454

7.  Central and Peripheral Administration of Fibroblast Growth Factor 1 Improves Pancreatic Islet Insulin Secretion in Diabetic Mouse Models.

Authors:  Katherine G Tennant; Sarah R Lindsley; Melissa A Kirigiti; Cadence True; Paul Kievit
Journal:  Diabetes       Date:  2019-05-02       Impact factor: 9.461

8.  Quantitative Whole-Body Imaging of I-124-Labeled Adeno-Associated Viral Vector Biodistribution in Nonhuman Primates.

Authors:  Douglas J Ballon; Jonathan B Rosenberg; Edward K Fung; Anastasia Nikolopoulou; Paresh Kothari; Bishnu P De; Bin He; Alvin Chen; Linda A Heier; Dolan Sondhi; Stephen M Kaminsky; Paul David Mozley; John W Babich; Ronald G Crystal
Journal:  Hum Gene Ther       Date:  2020-12       Impact factor: 5.695

Review 9.  Translation of MicroRNA-Based Huntingtin-Lowering Therapies from Preclinical Studies to the Clinic.

Authors:  Jana Miniarikova; Melvin M Evers; Pavlina Konstantinova
Journal:  Mol Ther       Date:  2018-02-08       Impact factor: 11.454

10.  Nanotransducers for Wireless Neuromodulation.

Authors:  Xiuying Li; Hejian Xiong; Nicholas Rommelfanger; Xueqi Xu; Jonghae Youn; Paul A Slesinger; Guosong Hong; Zhenpeng Qin
Journal:  Matter       Date:  2021-05-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.